People: Acasti Pharma Inc (ACST.O)

ACST.O on Consolidated Issue listed on NASDAQ Capital Market

0.49USD
17 Dec 2014
Price Change (% chg)

$-0.05 (-8.65%)
Prev Close
$0.54
Open
$0.52
Day's High
$0.52
Day's Low
$0.49
Volume
74,835
Avg. Vol
256,489
52-wk High
$1.56
52-wk Low
$0.35

Search Stocks

Summary

Name Age Since Current Position

Jerald Wenker

2014 Chairman of the Board

Andre Godin

2014 Interim President and Chief Executive Officer

Pierre Lemieux

2010 Chief Operating Officer

Harlan Waksal

60 2013 Executive Vice President - Business and Scientific Affairs, Director

Tina Sampalis

2012 Chief Global Strategy Officer

Ronald Denis

2014 Director

Henri Harland

2014 Director

Valier Boivin

2013 Independent Director

Jean-Claude Debard

2013 Independent Director

Reed Tuckson

2013 Independent Director

Biographies

Name Description

Jerald Wenker

Mr. Jerald J. Wenker is a Chairman of the Board of Acasti Pharma Inc., Mr. Wenker is currently President and Chief Operating Officer of Dermalogica, a leading professional skin care company based in the United States. Previously, he was President of Ther-Rx Corporation, the branded division of KV Pharmaceuticals. Prior to Ther-Rx, Mr. Wenker worked at Abbott Laboratories for approximately 15 years where he held several executive roles in such areas as commercial and marketing management, strategic planning, licensing and new business development as well as new product development. Mr. Wenker holds a Master of Science in Marketing from Northwestern University’s J.L. Kellogg Graduate School of Management.

Andre Godin

Mr. Andre Godin an Interim President and Chief Executive Officer of Acasti Pharma Inc., Andre has been with Neptune since 2003 and has played an active leadership role in all aspects of the organization. He is a chartered professional accountant and also has more than 20 years of industry experience, including as former president of a dietary supplement company and as a corporate controller for a pharmaceutical company in over-the-counter (OTC) products.

Pierre Lemieux

Dr. Pierre Lemieux Ph.D. is a Chief Operating Officer of Acasti Pharma Inc., Dr. Pierre Lemieux has been the Chief Operating Officer of the Corporation since April 12, 2010. He holds a post-doctoral degree in Oncology from the Health Science Center, University of Texas (San Antonio), United States, and a PhD in biochemistry from Laval University, Canada, jointly with University of Nottingham, England. Prior to joining the Corporation, Dr. Lemieux was the President, Chief Executive Officer and the chairman of the board as well as being the founder of Technologie Biolactis Inc., a late-stage biotechnology company specialized in the valorization of proteins to better serve the nutraceutical, cosmetic and pharmaceutical industries.

Harlan Waksal

Dr. Harlan W. Waksal, M.D., serves as Executive Vice President - Business and Scientific Affairs, Director of Acasti Pharma Inc., Dr. Harlan W. Waksal is a retired physician. Dr. Waksal is the Vice-President, Business and Scientific Affairs at Acasti. He received his B.A. from Oberlin College and M.D. from Tufts University School of Medicine, and his post graduate training in Internal Medicine and in Pathology. In addition, he did research in immunology at the Weizmann Institute of Science. Dr. Waksal was a founder of Imclone Systems Incorporated; a New York based pharmaceutical company specializing in developing new treatment for various forms of cancer. He served as the Chief Operating Officer and member of the Board of Directors from 1986 until 2001 and as President/CEO from 2001 until 2002. During his tenure, he was responsible for building the scientific and operation infrastructure of the company. Dr. Waksal is the author of over 50 scientific publications and has been the author of multiple patents and patent applications. His current activities are focused on managing various real estate developments and serving on select Board of Directors. Dr. Waksal currently serves on the Boards of the Oberlin College, Senesco Technologies, Inc. He also serves on the Advisory Board of Northern Rivers Funds.

Tina Sampalis

Dr. Tina Sampalis M.D., Ph.D. is a Chief Global Strategy Officer of Acasti Pharma Inc., Dr. Tina Sampalis is the Chief Global Strategy Officer of the Corporation. Dr. Sampalis is an Oncology Surgeon, trained in Physiology at McGill University, Medicine at the University of Patras (Greece), Dermatology at Göttingen University (Germany) and Marselisborg University (Denmark), Pediatric, General and Oncology Surgery at the University of Athens (Greece), graduate training (PhD) in Surgical Research at the University of Athens and a second PhD in Epidemiology and Experimental Surgery at McGill University. Between May 2000 and June 2007, she held the position of Vice-President of Research and Business Development at Neptune and since June 2007 the position of Chief Scientific Officer of the Corporation. She ceased to occupy these positions following her nomination as Chief Global Strategy Officer for Neptune and Acasti, which was announced on May 25, 2012.

Ronald Denis

Dr. Ronald Denis is Director of Acasti Pharma Inc. Dr. Ronald Denis has been Chief of Surgery and director of the Trauma Program at Hôpital du Sacré-Coeur in Montréal since 1997. Since 1987, Dr. Denis has also been medical co-director of the Canadian Formula 1 Grand Prix. Dr. Denis sits on several scientific boards and management committees.

Henri Harland

Mr. Henri Harland serves as Director of Acasti Pharma Ltd. He resigned as President, Chief Executive Officer of the Company effective April 28, 2014. Mr. Harland is an Actuary and holds a MBA (Finance) from Laval University. Mr. Henri Harland has been a director as well as the President and Chief Executive Officer of Neptune since its incorporation on October 9, 1998. He is the founder of the Corporation and of Neptune and has been involved in the krill research project since 1991. For more than ten years he has held the position of President and Chief Executive Officer of Gestion Harland Inc., a financial engineering group. Previously, he acted as an independent financial consultant for companies in different industrial sectors in both North America and Europe guiding them through recapitalization, financing and business development.

Valier Boivin

Mr. Valier Boivin is an Independent Director of Acasti Pharma Inc., Mr. Valier Boivin holds a bachelor’s degree in Economic and Administrative Sciences (UQAC-1973), a master’s degree in Taxation (Université de Sherbrooke, 1978) and a law degree (Université de Montréal, 1985). He has also been a member of the “Barreau du Québec” since 1986 and the “Ordre des comptables agréés du Québec” since 1974. He held the position of Professor at the Université du Québec à Chicoutimi until 1978 and then joined the master’s degree in taxation program as Professor at the Université de Sherbrooke until 1987. Founder (in 1987) of Boivin O’Neil, s.e.n.c., he also practices business law. Specialized in mergers & acquisitions and corporate financing, he acts as legal and strategic counsel to many private and public companies. Since January 2009, he has occupied the position of President of the regional economic intervention fund, FIER Ville-Marie, L.P. Mr. Boivin is also socially involved with various professional associations, non-profit organizations and charitable foundations.

Jean-Claude Debard

Mr. Jean-Claude Debard is an Independent Director of Acasti Pharma Inc., Mr. Jean-Claude Debard has been President of M Motors Automobiles France, Subaru France, Daihatsu France, SsangYong France since 2012 and FEA Services as well as an officer of Frey Accessories and Parts since 1999 and most recently Executive President of Group Emil Frey France since 2008. Since 1999, Mr. Debard has served on the Oversight Committee of Holding (SERGESA), SsangYong France and Hyundai Finances. Mr. Debard also has a graduate degree in Management and Strategic Management.

Reed Tuckson

Dr. Reed V. Tuckson, M.D., has been appointed as an Independent Director of Acasti Pharma Inc., with effect from 5 November 2013. Dr. Tuckson is currently the managing director of Tuckson Health Connections LLC, a health and medical care consulting business. Previously, he served a long tenure as executive vice-president and chief of medical affairs for UnitedHealth Group, a Fortune 25 health and well-being company, which includes the United States' largest health insurer and the industry's most comprehensive health services company. Among his many committee memberships, Dr. Tuckson is member of the advisory committee to the director of the National Institutes of Health and is also an active member of the Institute of Medicine of the National Academy of Sciences. He also serves on the boards of the American Telemedicine Association, Howard University and Cell Therapeutics Inc., a public corporation. Dr. Tuckson has been noted several times by Modern Healthcare Magazine as one of the 50 most powerful physician executives in health care and Black Enterprise Magazine featured him as one of the most powerful executives in corporate America. Dr. Tuckson is a graduate of Howard University, Georgetown University's school of medicine, and the hospital of the University of Pennsylvania's general internal medicine residency and fellowship programs, where he was also a Robert Wood Johnson Foundation clinical scholar studying at the Wharton School of Business.

Basic Compensation

Name Fiscal Year Total

Jerald Wenker

--

Andre Godin

89,100

Pierre Lemieux

479,813

Harlan Waksal

1,219,480

Tina Sampalis

101,975

Ronald Denis

--

Henri Harland

740,379

Valier Boivin

--

Jean-Claude Debard

--

Reed Tuckson

--
As Of 27 Feb 2014
Search Stocks